Promise Study

‼️ The PANGEA Model is out now @TheLancetHaem ‼️ A 🧵on how PANGEA improves prediction accuracy of MGUS & SMM progression to #MultipleMyeloma & is the 1st model that is #personalized to the individual #mmsm patient! @LabGhobrial @DanaFarber | 1/ sciencedirect.com/science/articl…

At the Ghobrial Lab retreat, Dr.Ghobrial & Dr.Khoury discussed the prevalence of monoclonal gammopathies & clinical outcomes screened by mass spectrometry. This new technology, quantitative MALDI-TOF Mass Spectrometry, defines better outcomes for precursor conditions to Myeloma.

Check out this article featuring Dr. Irene Ghobrial that discusses Multiple Myeloma in the Black Community. The article addresses questions and topics that fuel the PROMISE Study's commitment to research and early detection, especially in the Black Community.

The PROMISE Study wishes you a Happy New Year! Start the new year with a more complete understanding of your health by screening for Myeloma precursor conditions. We are asking for blood samples that we will analyze to test for multiple myeloma precursor conditions.

Happy Holidays from the PROMISE Study! Give the gift of knowledge this holiday season and encourage your family and friends to find out if they are eligible for myeloma screening today! Enroll now at enroll.promisestudy.org.

Help us tackle Multiple Myeloma this football season. While your favorite team is taking a break during halftime, take some time to learn if you are at a high risk for Myeloma precursors and complete the eligibility survey! Enroll today at enroll.promisestudy.org.

Closing off #ASH22 with @IreneGhobrial receiving the Dameshek Prize. It is a privilege and honor to be mentored by one of the most passionate and talented physician-scientists out there. Thank you for everything you do for your patients and trainees! @LabGhobrial

Promise in South Africa. @PromiseStudy David Lee #3216  Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa  ash.confex.com/ash/2022/webpr…

Persistence of MGIP and MGUS by mass spec. Habib El-Khoury #4538  Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study  ash.confex.com/ash/2022/webpr…

Light chains mesures in African Americans with no renal dysfunction. Luca Bertamini #4495  Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy  ash.confex.com/ash/2022/webpr…

The @PromiseStudy team will be at our booth 2419 in the exhibit hall today at 1:00 pm to share information about this first-of-its-kind screening study for #multiplemyeloma. Come learn more at 1:00 pm. #ASH22 ms.spr.ly/6014eK8Qw

The master of single cell @ash22 #mmsm ⁦@RomanosSP⁩ ⁦@gaddyg⁩ ⁦@getz_lab⁩ ⁦@LabGhobrial⁩

Some of our lab and clinical team pics ⁦@LabGhobrial⁩ ⁦@getz_lab⁩ ⁦@DanaFarber⁩ #ash22

Did you know? The PROMISE Study screens people at a high risk of developing precursors to myeloma, including: - People with a parent, sibling, or child with multiple myeloma or one of its early warning signs - African Americans - People with multiple myeloma precursor conditions

Did you know? Most people with precursor conditions typically do not experience symptoms. Since doctors rarely screen for them, precursor conditions are often never detected until they have progressed to a more advanced stage.

Did you know? Precursor conditions are early blood conditions that may or may not develop into cancers such as Lymphoma, Leukemia, Waldenström's Macroglobulinemia, and Multiple Myeloma. Multiple myeloma is blood cancer found in the bone marrow.

Thank you to everyone who joined us this weekend at the Men's Health Huddle in Tampa! In video below, Dr. Blue encourages the Black community over 30 to screen with PROMISE! You can also screen if you have a first degree family member with blood cancer or related blood condition.

Join us for an informative event October 26th 6:30-8pm via zoom! "Let's talk about blood cancer: A night of education about Multiple Myeloma" Hope to see you there. Register Here: bit.ly/DFCI1026

The PROMISE Study team will be offering free screenings in Tampa, Florida at the Moffitt Cancer Center this Saturday, October 22! The fair will run from 10am-3pm with screenings starting at 11am.